Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
Adult
Chemoradiotherapy, Adjuvant
/ methods
Disease-Free Survival
Female
Humans
Lymph Node Excision
Lymph Nodes
/ pathology
Lymphatic Metastasis
/ therapy
Male
Middle Aged
Neoadjuvant Therapy
/ methods
Neoplasm Recurrence, Local
/ epidemiology
Neoplasm Staging
Rectal Neoplasms
/ diagnosis
Retrospective Studies
Risk Factors
Lateral lymph node dissection
Locoregional recurrence
Lymphatic metastasis
Neoadjuvant therapies
Rectal neoplasms
Total mesorectal excision
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Jun 2020
07 Jun 2020
Historique:
received:
07
01
2020
revised:
17
04
2020
accepted:
28
04
2020
entrez:
20
6
2020
pubmed:
20
6
2020
medline:
1
4
2021
Statut:
ppublish
Résumé
Lateral lymph node metastasis is one of the leading causes of local recurrence in patients with advanced mid or low rectal cancer. Neoadjuvant chemoradiotherapy (NCRT) can effectively reduce the postoperative recurrence rate; thus, NCRT with total mesorectal excision (TME) is the most widely accepted standard of care for rectal cancer. The addition of lateral lymph node dissection (LLND) after NCRT remains a controversial topic. To investigate the surgical outcomes of TME plus LLND, and the possible risk factors for lateral lymph node metastasis after NCRT. This retrospective study reviewed 89 consecutive patients with clinical stage II-III mid or low rectal cancer who underwent TME and LLND from June 2016 to October 2018. In the NCRT group, TME plus LLND was performed in patients with short axis (SA) of the lateral lymph node greater than 5 mm. In the non-NCRT group, TME plus LLND was performed in patients with SA of the lateral lymph node greater than 10 mm. Data regarding patient demographics, clinical workup, surgical procedure, complications, and outcomes were collected. Multivariate logistic regression analysis was performed to evaluate the possible risk factors for lateral lymph node metastasis in NCRT patients. LLN metastasis was pathologically confirmed in 35 patients (39.3%): 26 (41.3%) in the NCRT group and 9 (34.6%) in the non-NCRT group. The most common site of metastasis was around the obturator nerve (21/35) followed by the internal iliac artery region (12/35). In the NCRT patients, 46% of patients with SA of LLN greater than 7 mm were positive. The postoperative 30-d mortality rate was 0%. Two (2.2%) patients suffered from lateral local recurrence in the 2-year follow up. Multivariate analysis showed that cT4 stage (odds ratio [OR] = 5.124, 95% confidence interval [CI]: 1.419-18.508; NCRT is not sufficient as a stand-alone therapy to eradicate LLN metastasis in lower rectal cancer patients and surgeons should consider performing selective LLND in patients with greater LLN SA diameter, poorer histological differentiation, or advanced T stage. Selective LLND for NCRT patients can have a favorable oncological outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Lateral lymph node metastasis is one of the leading causes of local recurrence in patients with advanced mid or low rectal cancer. Neoadjuvant chemoradiotherapy (NCRT) can effectively reduce the postoperative recurrence rate; thus, NCRT with total mesorectal excision (TME) is the most widely accepted standard of care for rectal cancer. The addition of lateral lymph node dissection (LLND) after NCRT remains a controversial topic.
AIM
OBJECTIVE
To investigate the surgical outcomes of TME plus LLND, and the possible risk factors for lateral lymph node metastasis after NCRT.
METHODS
METHODS
This retrospective study reviewed 89 consecutive patients with clinical stage II-III mid or low rectal cancer who underwent TME and LLND from June 2016 to October 2018. In the NCRT group, TME plus LLND was performed in patients with short axis (SA) of the lateral lymph node greater than 5 mm. In the non-NCRT group, TME plus LLND was performed in patients with SA of the lateral lymph node greater than 10 mm. Data regarding patient demographics, clinical workup, surgical procedure, complications, and outcomes were collected. Multivariate logistic regression analysis was performed to evaluate the possible risk factors for lateral lymph node metastasis in NCRT patients.
RESULTS
RESULTS
LLN metastasis was pathologically confirmed in 35 patients (39.3%): 26 (41.3%) in the NCRT group and 9 (34.6%) in the non-NCRT group. The most common site of metastasis was around the obturator nerve (21/35) followed by the internal iliac artery region (12/35). In the NCRT patients, 46% of patients with SA of LLN greater than 7 mm were positive. The postoperative 30-d mortality rate was 0%. Two (2.2%) patients suffered from lateral local recurrence in the 2-year follow up. Multivariate analysis showed that cT4 stage (odds ratio [OR] = 5.124, 95% confidence interval [CI]: 1.419-18.508;
CONCLUSION
CONCLUSIONS
NCRT is not sufficient as a stand-alone therapy to eradicate LLN metastasis in lower rectal cancer patients and surgeons should consider performing selective LLND in patients with greater LLN SA diameter, poorer histological differentiation, or advanced T stage. Selective LLND for NCRT patients can have a favorable oncological outcome.
Identifiants
pubmed: 32550762
doi: 10.3748/wjg.v26.i21.2877
pmc: PMC7284184
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2877-2888Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare there is no conflict of interest in regard to this research.
Références
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
Br J Surg. 2011 Dec;98(12):1798-804
pubmed: 21928408
Eur J Cancer. 1995 Jul-Aug;31A(7-8):1229-32
pubmed: 7577028
Dis Colon Rectum. 2003 Mar;46(3):333-9
pubmed: 12626908
J Am Coll Surg. 1997 May;184(5):475-80
pubmed: 9145067
Surgery. 2017 Aug;162(2):303-314
pubmed: 28366499
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S614-20
pubmed: 25896145
Ann Surg. 2016 Aug;264(2):323-9
pubmed: 26692078
Br J Surg. 2008 Jan;95(1):33-49
pubmed: 18165939
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281
J Surg Res. 2018 Sep;229:134-144
pubmed: 29936980
J Endourol. 2016 May;30 Suppl 1:S2-7
pubmed: 26971898
Dis Colon Rectum. 1959 Mar-Apr;2(2):169-72
pubmed: 13652786
Ann Surg. 2009 Feb;249(2):229-35
pubmed: 19212175
AJR Am J Roentgenol. 2014 Jun;202(6):1245-55
pubmed: 24848821
Dis Colon Rectum. 2001 Sep;44(9):1274-80
pubmed: 11584199
Ann Surg. 2012 Jun;255(6):1129-34
pubmed: 22549752
Dis Colon Rectum. 2013 Dec;56(12):1339-48
pubmed: 24201387
Anat Rec. 1950 Dec;108(4):635-44
pubmed: 14799884
J Surg Oncol. 2015 Mar 15;111(4):459-64
pubmed: 25559888
Ann Surg Oncol. 2014 Jul;21(7):2280-7
pubmed: 24604580
Cancer. 2017 May 1;123(9):1497-1506
pubmed: 28295220
Br J Surg. 2005 Jun;92(6):756-63
pubmed: 15838895
Eur J Surg Oncol. 2018 Apr;44(4):463-468
pubmed: 29428473
J Clin Oncol. 2015 Jun 1;33(16):1797-808
pubmed: 25918296
Lancet Oncol. 2012 Jun;13(6):616-21
pubmed: 22591948
Eur J Surg Oncol. 2016 Dec;42(12):1851-1858
pubmed: 27519616
Int J Clin Oncol. 2012 Feb;17(1):1-29
pubmed: 22002491
Dis Colon Rectum. 2017 May;60(5):469-476
pubmed: 28383446
Surg Gynecol Obstet. 1952 Aug;95(2):229-42
pubmed: 14950656
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Ann Surg Oncol. 2008 Mar;15(3):729-37
pubmed: 18057989
J Anus Rectum Colon. 2019 Oct 30;3(4):175-195
pubmed: 31768468
Lancet Oncol. 2009 Nov;10(11):1053-62
pubmed: 19767239
Ann Surg Oncol. 2009 Oct;16(10):2779-86
pubmed: 19626377
Eur Radiol. 2013 Sep;23(9):2522-31
pubmed: 23743687
Dis Colon Rectum. 1989 Feb;32(2):128-33
pubmed: 2914526
Ann Surg. 2017 Aug;266(2):201-207
pubmed: 28288057